World-Renowned Authority Uncovers a Medical Milestone!

Silver in 2009, cryptocurrency in 2017, and cannabis in 2018 – history shows that if you got into the right commodity and the right stocks at the right time, you could have quickly increased your wealth by many multiples. The next opportunity is now upon us as a new market is ripe for the picking for early-stage investors.

How early? I’ll put it to you this way: there’s an industry where only a small handful of experts actually exist in the area. Government interference made it impossible to conduct research on this product type, though the barriers to scientific study and analysis are being removed in our lifetime.

You might be thinking that this sounds a lot like cannabis, and you’re not that far off. Cannabis was demonized for decades before the laws and regulations in many states and countries were relaxed recently. I sent out alerts on a number of handpicked cannabis stocks when I saw that the time was right, and they all did a moon landing before I advised people to take profits.

To get the big picture of what the next moonshot commodity will be, I spoke with one of the world’s few recognized experts in the area of psychedelic medicine for mood disorders. His name is Dr. Roger McIntyre, and you’ll want to remember that name because his vision could lead to a lot of healing in the world, along with a terrific year for investors.

Dr. McIntyre recently accepted the position of Chief Executive Officer at Champignon Brands (CSE: SHRM, OTC: SHRMF), a company that specializes in exploratory medicinal solutions enhanced with ketamine, psilocybin, and other psychedelics.

A Professor of Psychiatry and Pharmacology at the University of Toronto, Dr. McIntyre has dedicated many years to helping people who suffer from the terrible struggles of depression, anxiety, and post-traumatic stress disorder.

As he explains in this power-packed interview, psychedelics got a bad rap as a “counterculture” drug of choice in the 1960s and 1970s. This led to a government ban on what could have been vital research into mushroom-based mood disorder healing agents.

Today, however, the medical research landscape is changing for the better. In fact, within the last two to three years, the FDA has identified psychedelics as a potential breakthrough in psychiatric drug discovery and development.

For over 20 years, Dr. McIntyre has run the world’s largest depression research organization by footprint. Amazingly, his lab has been able to target the areas of the brain affected by depression, PTSD, and drug/alcohol misuse. Dr. McIntyre has personally seen the positive impact of psychedelic medicine on these debilitating conditions.

For prospective investors in this exciting field of medicine, Champignon Brands offers a cutting-edge entry point. The company’s vision is already coming to fruition with a clinic in California dedicated to pursuing psychedelic-based medicine. Along with that, Champignon is in late-stage talks with clinics in Texas, Florida, and New York.

But you don’t have to wait for the next game-changing medical solution to be discovered since SHRM/SHRMF shares are already available for trading. And don’t miss my complete interview with Dr. McIntyre for the full details on how a groundbreaking class of medicines, once unavailable to the scientific community, will soon change the world.

The psychedelic sector is LIFTING OFF and this company could be the biggest beneficiary


    We are not brokers, investment or financial advisers, and you should not rely on the information herein as investment advice. We are a marketing company. If you are seeking personal investment advice, please contact a qualified and registered broker, investment adviser or financial adviser. You should not make any investment decisions based on our communications. You should know that we have been compensated three hundred thousand dollars, directly by the company, for a two year public awareness campaign. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT recommendations. The securities issued by the companies we profile should be considered high risk and, if you do invest, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEC filings, press releases, and risk disclosures. Information contained in this profile was provided by the company, extracted from SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.

    Please read our full disclaimer at WealthResearchGroup.com/disclaimer